Effects of Newer Antipsychotics on Extrapyramidal Function
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 16 (1), 23-45
- https://doi.org/10.2165/00023210-200216010-00003
Abstract
Following acceptance of clozapine as a superior antipsychotic agent with low risk of adverse extrapyramidal syndromes (EPS), such as dystonia, parkinsonism, akathisia or tardive dyskinesia, several...Keywords
This publication has 218 references indexed in Scilit:
- Binding of antipsychotic drugs to human brain receptorsLife Sciences, 2000
- Risperidone in the Treatment of Patients With Alzheimer's Disease With Negative SymptomsInternational Psychogeriatrics, 2000
- ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophreniaClinical Therapeutics, 1995
- Suppression of dyskinesias in advanced Parkinson's disease: Moderate daily clozapine doses provide long‐term dyskinesia reductionMovement Disorders, 1994
- Psychiatric Manifestations of Olivo-Ponto-Cerebellar Atrophy and Treatment with ClozapineThe International Journal of Psychiatry in Medicine, 1993
- Nocturnal akathisia in parkinson's disease: Treatment with clozapineMovement Disorders, 1993
- Neuroleptic Malignant SyndromeJournal of Clinical Psychopharmacology, 1986
- Clozapine versus Perphenazine: The Value of the Biochemical Mode of Action of Neuroleptics in Predicting their Therapeutic ActivityThe British Journal of Psychiatry, 1976
- CLOZAPINE AND HALOPERIDOL IN A SINGLE‐BLIND CROSS‐OVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIAActa Psychiatrica Scandinavica, 1974
- Attempted use of haloperidol in the treatment of L-dopa induced dyskinesiasJournal of Neurology, Neurosurgery & Psychiatry, 1974